BioSpace News Archive

Viracta Therapeutics, Inc. today announced that it has been selected for addition to the Nasdaq Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 20, 2021.

Anixa Biosciences, Inc. today announced that the Company is participating in the LifeSci Partners 11th Annual Corporate Access Event, which will be held virtually from January 5-7 , 2022.

Theseus Pharmaceuticals, Inc. today announced the appointment of Alicja Januszewicz , Ph.D. as Senior Vice President, People and Culture.

Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF) (FSE:4PC) (“Perimeter” or the “Company”), a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, announced the initiation of a multi-center, randomized, two-arm pivotal clinical trial to evaluate its Perimeter B-Series OCT with ImgAssist AI for use during breast conservation surgery.

Epic Sciences, Inc. announces DefineMBC, a novel metastatic breast cancer test that includes both cell-based and cell-free analysis from a single blood draw.

INVO Bioscience, Inc., a medical device company focused on commercializing the world’s only in vivo culture system, INVOcell®, announced the Company has entered into an expanded agreement with Ovoclinic, a group of clinics specialized in assisted reproductive treatments with four locations across Spain and collaborating centers around Europe, to accelerate adoption of INVOcell within their markets.

Douglas Pharmaceuticals Ltd (Douglas), today announced positive top-line data from its multinational, randomized, placebo-controlled, double-blind Phase 2 study of R-107 designed to investigate the efficacy and safety of R-107 (ketamine 30, 60, 120 or 180 mg) versus placebo for TRD.

SureClinical, a leading provider of cloud-native eClinical applications, announced today the launch of their new Eclinical Ecosystem ECO Applications and Platform Bundle.

Know Labs, Inc. (OTCQB: KNWN), an emerging leader in non-invasive medical diagnostics, today announced that a new subsidiary created to work with the company’s Artificial Intelligence (AI) Deep Learning Platform has generated initial revenue of approximately $4.2 million from Non-Fungible Token (NFT) sales.

Altamira Therapeutics Ltd., a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, announced that the first group of patients has been randomized in a clinical trial with Bentrio™ in house dust mite allergic rhinitis.